Similarly, in breast carcinoma, high p16 immunoreactivity is significantly correlated with more undifferentiated and malignant phenotypes (i.e., estrogen receptor negativity and higher nuclear grade) [13]. The gene discussed is CDKN2A; the disease is breast carcinoma.